


Understanding PRO Requirements in HTA across Europe

Case Study | HTA across Europe

Development of a project to enhance understanding of PRO requirements across Europe



Background

A pharmaceutical sponsor requested to partner with Clarivate to better understand the PRO requirements in HTA across specific markets in Europe.

The Challenge

One of the aims of this work was a call to harmonise the methods used to assess PRO data in European countries.

The Solution

Clarivate Commercial Consulting

Clarivate's Clinical Outcome Assessment (COA) team and Commercial Consulting team partnered to provide a project tailored to meet a pharmaceutical sponsor's need to understand the PRO requirements across Europe:

- A targeted literature review was conducted to identify PRO-related data specifications for HTA in European markets. The main aim of this activity was to inform an interview guide for qualitative interviews with key opinion leaders (KOLs).
- Twelve KOLs from England, France and Germany were interviewed to gain their expert perspectives on PRO and HTA practices and identify areas for harmonisation across European markets.
- The COA and Commercial Consulting teams worked together to combine their expertise in COA requirements, HTA knowledge and primary research with KOLs to answer the sponsor's questions in an efficient manner.

The Results

Delivered key strategic considerations for preparing PRO data for HTA



An in-depth PowerPoint report was developed to present the study results to the sponsor, noting a lack of transparency and harmonisation of PRO data collection and reporting in key European markets, along with strategic considerations for sponsors preparing PRO data for HTA submissions



Dissemination work to share findings within the field including:

- ISPOR 2025 oral presentation
- Manuscript in development

[Click here to learn more](#)

Discover solutions at:

clarivate.com